AstraZeneca delivers strong Q2 2025 results with double-digit revenue growth and robust pipeline progress
Overview AstraZeneca delivered another quarter of strong financial and operational performance in Q2 2025, supported by double-digit revenue growth across Oncology, BioPharmaceuticals, and Rare Disease. The company benefited from sustained global demand, the successful rollout of new therapies, and disciplined cost management. Clinical development advanced significantly, with 12 positive Phase III readouts across key therapy…
